Valantine Hannah sold $1.0M of CDNA
Valantine Hannah sold 28,779 shares of CareDx, Inc. (CDNA) at an average of $36.15 ($36.14–$36.55, $1.04M total) across 2 trades on 2026-07-16 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a concrete datapoint on director selling activity, but it does not include new guidance, financial results, or operational events.
Market read
CDNA receives a fresh insider-selling datapoint (about $1.04M) with limited expected impact due to 10b5-1 context.
What to watch
Traders may over-weight insider sales; the key incremental data here is the exact share count, price range, and post-transaction holdings, not a new operating development.
Background
The article is an SEC Form 4 insider transaction disclosure for CareDx, Inc. (CDNA).
Ticker impact
CareDx director Valantine Hannah sold about 28,779 shares in open-market trades totaling $1.04M under a 10b5-1 plan.
Likely limited, short-lived sentiment impact; no clear directional signal beyond routine 10b5-1 selling.
The filing specifies a pre-arranged Rule 10b5-1 plan, which typically reduces the signal strength of insider sales versus discretionary selling.
Market effects
Minimal; this is company-specific insider transaction disclosure with no sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity rather than negative expectations.
Key entities
- issuerCareDx, Inc.
Company whose director insider sale is disclosed on Form 4.
- insiderValantine Hannah
Director who executed open-market sales under a pre-arranged 10b5-1 plan.
